# US 2001/0026796 A1 · TCL1 enhances Akt kinase activity and mediates its nuclear translocation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026796 A1
- Document ID: US20010026796A1
- Status: Published application
- Kind: A1
- Application number: 09/804,656
- Filed: 2001-03-13
- Published: 2001-10-04
- Earliest claimed: 2000-03-14
- Inventors: Carlo M. Croce; Yuri Pekarsky
- Web page: https://patentgrep.com/patent/US20010026796A1

## CPC

- G01N 33/57505: of the blood, e.g. leukaemia
- A61K 38/45: Transferases (2)
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The TCL1 oncogene at 14q32.1 is involved in the development of human leukemia. This invention demonstrates the interaction between the Tcl1 and the Akt1 proteins. The physical interaction between endogenous Akt1 and Tcl1 occurs through the PH domain of the Akt1 protein. The present invention relates to the identification of Tcl1 mimics and Tcl1 antagonists that modifying this interaction, with the subsequent modification of apoptotic and proliferative signals.

## Claims

### Claim 1

An antibody which binds to an epitope on Tcl1, wherein said antibody modulates an interaction between said epitope and an Akt1 kinase.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein said antibody modulates a Tcl1 enhanced kinase activity of said Akt1 kinase.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein said antibody comprises a monoclonal antibody.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein said antibody comprises a polyclonal antibody.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising an antibody of claim 1.

### Claim 6 (depends on 1)

A method of treating a disease state in which the activity of an Akt1 kinase is altered in a mammal, comprising administering to said mammal a therapeutically effective amount of said antibody of claim 1, wherein said antibody binds to an epitope on a Tcl1 protein, thereby modulating a Tcl1 enhanced kinase activity of said Akt1 kinase.

### Claim 7 (depends on 6)

The method of claim 6, wherein said disease state is a T-cell leukemia or T-cell lymphoma.

### Claim 8 (depends on 7)

The method of claim 7, wherein said T-cell leukemia or T-cell lymphoma is associated with a chromosome 14 abnormality, said chromosome abnormality further comprises a t(14;14) (q11;q32) translocation or an inv (14) (q11;132) inversion.

### Claim 9

A method of treating a disease state in which the activity of an Akt1 kinase is altered in a mammal, comprising administering to said mammal a therapeutically effective amount of a peptide fragment of an Akt1 kinase, said peptide fragment further comprising a PH domain, wherein said peptide fragment binds to said Akt kinase, thereby modulating a Tcl1enhanced kinase activity of said Akt1 kinase.

### Claim 10 (depends on 9)

The method of claim 9, wherein said disease state is a T-cell leukemia or T-cell lymphoma.

### Claim 11 (depends on 10)

The method of claim 10, wherein said T-cell leukemia or T-cell lymphoma is associated with a chromosome 14 abnormality, said chromosome abnormality further comprising a t(14;14) (q11;q32) translocation or an inv (14) (q11;132) inversion.

### Claim 12 (depends on 10)

The method of claim 10, wherein said peptide fragment comprises a PH domain, wherein said PH domain competitively binds to an Akt1 binding domain on a Tcl1 protein.

### Claim 13

A pharmaceutical composition comprising a peptide fragment of an Akt1 kinase, said peptide fragment comprising a PH domain.

### Claim 14

A compound comprising a Tcl1 mimic, wherein said Tcl1 mimic binds to an Akt1 kinase in any cell and is functionally active in mimicking a Tcl1 enhanced activation of said Akt1 kinase.

### Claim 15

A method of identifying a molecule that specifically binds to an Atk1 kinase and is functionally active in mimicking a Tcl1 enhanced activation of said Akt1 kinase, comprising
a) contacting said Akt1 kinase with a plurality of molecules under conditions conducive to binding between said Akt1 kinase and said molecules; and
b) identifying a molecule within said plurality that specifically binds to said Akt1 kinase and is functionally active in mimicking said Tcl1 enhanced activation.

### Claim 16

A method of treating a disease state in which the activity of an Akt1 kinase is altered in a mammal, comprising administering to said mammal a therapeutically effective amount of a Tcl1 mimic, wherein said Tcl1 mimic binds to said Akt1 kinase, thereby activating a Tcl1 enhanced kinase activity of said Akt1 kinase.

### Claim 17 (depends on 16)

The method of claim 16, wherein said disease state comprises a degenerative disease.

### Claim 18

A pharmaceutical composition comprising a Tcl1 mimic, wherein said Tcl1 mimic activates a Tcl1 enhanced kinase activity of an Akt1 kinase.

### Claim 19

A compound comprising a Tcl1 antagonist, wherein said Tcl1 antagonist binds to an Akt1 kinase in any cell and is functionally active in modulating a Tcl1 enhanced activation of said Akt1 kinase.

### Claim 20

A method of identifying a molecule that specifically binds to an Atk1 kinase and is functionally active in antagonizing a Tcl1 enhanced activation of said Akt1 kinase, comprising
a) contacting said Akt1 kinase with a plurality of molecules under conditions conducive to binding between said Akt1 kinase and said molecules; and
b) identifying a molecule within said plurality that specifically binds to said Akt1 kinase and is functionally active in antagonizing said Tcl1 enhanced activation.

### Claim 21

A method of treating a disease state in which the activity of an Akt1 kinase is altered in a mammal, comprising administering to said mammal a therapeutically effective amount of a Tcl1 antagonist, wherein said Tcl1 antagonist binds to said Akt1 kinase, thereby inhibiting a Tcl1 enhanced kinase activity of said Akt1 kinase.

### Claim 22 (depends on 21)

The method of claim 21, wherein said disease state comprises a proliferative disorder.

### Claim 23

A pharmaceutical composition comprising a Tcl1 antagonist, wherein said Tcl1 antagonist inhibits a Tcl1 enhanced kinase activity of an Akt1 kinase.
